PT 107

Drug Profile

PT 107

Alternative Names: PT-107

Latest Information Update: 16 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pique Therapeutics
  • Developer Pique Therapeutics; Technomark Life Sciences
  • Class Antineoplastics; Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Non-small cell lung cancer

Most Recent Events

  • 07 Nov 2017 Positive efficacy and adverse events data from a phase II trial in non-small cell lung cancer released by Pique Therapeutics
  • 23 Jun 2015 Phase-II ongoing for non-small cell lung cancer in USA and India
  • 04 Jun 2013 Phase-II development is ongoing in USA & India
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top